Beam Therapeutics Reports Higher Q1 Loss, Projects Long-Term Stability Amid R&D Advances
Beam Therapeutics Inc. reported a $109.27 million loss in Q1 2025, exceeding last year’s figures and analyst expectations, but projects financial stability through 2028.
2 minutes to read